PMID- 21344733
OWN - NLM
STAT- MEDLINE
DCOM- 20110307
LR  - 20190713
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 91
IP  - 3
DP  - 2011 Feb 15
TI  - Calcineurin inhibitor-free monotherapy in human leukocyte antigen-identical live 
      donor renal transplantation.
PG  - 330-3
AB  - BACKGROUND: Most recent trials in human leukocyte antigen (HLA)-identical living 
      donor (LD) renal transplantation have used immunosuppressive regimens with no 
      induction therapy, corticosteroid-free long-term treatment, and calcineurin 
      inhibitor minimization. PATIENTS AND METHODS: Seven HLA-identical LD recipients 
      were prospectively enrolled. Immunosuppression included induction therapy with 
      antithymocyte globulins for 10 days and long-term monotherapy with mycophenolate 
      mofetil (2 g/day) in six cases and sirolimus (target trough levels: 6-10 ng/mL) 
      in the last case. A single preoperative steroid bolus was administered. RESULTS: 
      After a median follow-up time of 26 months (range: 5-50 months), patient and 
      graft survival was 100%. Only one patient experienced borderline lesions at 3 
      months and received steroids for a 5-month period. All patients had a protocol 
      biopsy at 3 months, and four had a second at 12 months. Acute cellular rejection 
      was not observed. Median serum creatinine at 3 months, 12 months, and last 
      follow-up were 103.1, 107.1, and 106.1 [mu]mol/L, respectively. For four 
      patients, measured glomerular filtration rate was evaluated at 3 months, and the 
      mean value was 71.2 mL/min/1.73 m2. CONCLUSIONS: Induction therapy with 
      antithymocyte globulins followed by mycophenolate mofetil or sirolimus 
      monotherapy provides excellent patient and graft survival, excellent renal 
      function, and no acute rejection episodes in HLA-identical LD renal transplant 
      recipients.
FAU - Venot, Marion
AU  - Venot M
AD  - Nephrology and Transplantation Department, Saint-Louis Hospital, Paris, France.
FAU - Abboud, Imad
AU  - Abboud I
FAU - Duboust, Alain
AU  - Duboust A
FAU - Michel, Catherine
AU  - Michel C
FAU - Suberbielle, Caroline
AU  - Suberbielle C
FAU - Verine, Jerome
AU  - Verine J
FAU - Flamant, Martin
AU  - Flamant M
FAU - Morelon, Emmanuel
AU  - Morelon E
FAU - Glotz, Denis
AU  - Glotz D
FAU - Peraldi, Marie-Noelle
AU  - Peraldi MN
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Antilymphocyte Serum)
RN  - 0 (Calcineurin Inhibitors)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - HU9DX48N0T (Mycophenolic Acid)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Antilymphocyte Serum/*therapeutic use
MH  - Biopsy
MH  - *Calcineurin Inhibitors
MH  - Female
MH  - Follow-Up Studies
MH  - Graft Survival/immunology
MH  - HLA Antigens/*immunology
MH  - Histocompatibility/immunology
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Kidney/pathology/physiology
MH  - Kidney Transplantation/*immunology
MH  - *Living Donors
MH  - Male
MH  - Middle Aged
MH  - Mycophenolic Acid/*analogs & derivatives/therapeutic use
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Sirolimus/*therapeutic use
MH  - Treatment Outcome
EDAT- 2011/02/24 06:00
MHDA- 2011/03/08 06:00
CRDT- 2011/02/24 06:00
PHST- 2011/02/24 06:00 [entrez]
PHST- 2011/02/24 06:00 [pubmed]
PHST- 2011/03/08 06:00 [medline]
AID - 10.1097/tp.0b013e3182033ef0 [doi]
PST - ppublish
SO  - Transplantation. 2011 Feb 15;91(3):330-3. doi: 10.1097/tp.0b013e3182033ef0.